High rate of prescriptions for new cholesterol medications never filled

September 27, 2017

In the first year of availability of the cholesterol lowering medications PCSK9 inhibitors, fewer than 1 in 3 adults initially prescribed one of these inhibitors actually received it, owing to a combination of out-of-pocket costs and lack of insurance approval, according to a study published by JAMA Cardiology.

Since 2015, PCSK9 inhibitors (PCSK9i), alirocumab and evolocumab, have been approved for adults with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated statin therapy and those with familial high cholesterol. The retail cost for these PCSK9i can be as much as $14,000 per year, leading health insurers and pharmacy benefit managers to implement utilization management processes including prior authorization and patient therapy copays. To date, limited information is available on how these preauthorization processes and copays jointly are associated with access to PCSK9i in community practice.

Using pharmacy transaction data, Ann Marie Navar, M.D., Ph.D., of the Duke Clinical Research Institute, Durham, N.C., and colleagues evaluated 45,029 patients who were newly prescribed PCSK9i in the United States between August 2015 and July 2016. Of patients given a new PCSK9i prescription, 51 percent were women, 57 percent were 65 years or older, and 53 percent had governmental insurance.

Of the patients given a prescription, 20.8 percent received approval on the first day, and 47.2 percent ever received approval. Of those approved, 65.3 percent filled the prescription, resulting in 30.9 percent of those prescribed PCSK9i ever receiving therapy. Patients who were older, male, and had atherosclerotic cardiovascular disease were more likely to be approved, but approval rates did not vary by patient LDL-C level nor statin use. Other factors associated with drug approval included having government vs commercial insurance, and those filled at a specialty vs retail pharmacy. Approval rates varied nearly 3-fold among the top 10 largest pharmacy benefit managers.

Not having a prescription filled by patients was most associated with copay costs, with prescription abandonment rates ranging from 7.5 percent for those with $0 copay to more than 75 percent for copays greater than $350.

Several limitations of the study are noted in the article.
-end-
For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/jamacardio.2017.3451)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Inhibitors Articles from Brightsurf:

New class of highly effective inhibitors protects against neurodegeneration
Heidelberg University neurobiologists have uncovered how a special receptor can lead to cell death.

Targeting SARS-CoV-2 enzyme with inhibitors
As the COVID-19 pandemic continues to spread, many researchers are studying epidemiological models to predict its propagation.

PD-1/PD-L1 inhibitors treatment in lung cancer: Brightness and challenge
Immune-checkpoint inhibitors (ICIs) have made a significant impact on the outcomes of lung cancer patients.

Designing peptide inhibitors for possible COVID-19 treatments
Scientists across the globe are rushing to find inhibitors of SARS-CoV-2, the new coronavirus behind the COVID-19 pandemic.

Oncotarget Early prediction of resistance to tyrosine kinase inhibitors
Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly monitored during the first month of therapy.

New screening method identifies inhibitors of cancer cell metabolism
A new screening system developed by scientists at the UCLA Jonsson Comprehensive Cancer Center leverages redundancy in an important component of a cell - nucleotide metabolism - to help identify new drugs that specifically and potently block processes that are essential for cancer cell growth.

Examining risk of suicide and use of ACE inhibitors, ARBs
Associations between risk of suicide and medications widely used in the management of high blood pressure, chronic kidney disease, heart failure and diabetes (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) were examined in this observational study.

MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy
A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, Ph.D., and Ann Richmond, Ph.D., has identified a possible second-line treatment for melanoma patients.

Proteasome inhibitors show promise for drug-resistant malaria
Proteasome inhibitors have significant promise as components of novel combination therapies to treat multidrug-resistant malaria, according to a study published June 6 in the open-access journal PLOS Pathogens by David Fidock, Caroline Ng, and Barbara Stokes of Columbia University Irving Medical Center, Matthew Bogyo of Stanford University School of Medicine, and colleagues.

IL-1 inhibitors may reduce radiation-induced vascular damage
Radiation therapy against cancer can increase the risk of cardiovascular disease much later in life, as the radiation causes chronic inflammation of the exposed blood vessels.

Read More: Inhibitors News and Inhibitors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.